medigraphic.com
ISSN 0016-3813 (Print)

2010, Number 6

<< Back Next >>

Gac Med Mex 2010; 146 (6)

Abordaje endonasal endoscópico transesfenoidal en adenomas hipofisiarios productores de hormona de crecimiento. Resultados preliminares

Rangel MCR, Santos-Franco JA, Sandoval-Balanzario MA, Saavedra-Andrade R, Velázquez-Chávez F, Dávila-Romero JC

Language: Spanish
References: 48
Page: 367-375
PDF size: 183.98 Kb.


ABSTRACT

Background: An endoscopic endonasal transsphenoidal approach is reported as less invasive, allowing an earlier discharge. Published series have never focused on its use in acromegalic patients. Objective: To assess the effectiveness of an endoscopic endonasal transsphenoidal approach in the management of growth hormone-secreting adenomas. Patients and methods: Nineteen consecutively operated patients were assessed with a prospective follow-up of one year. Results: Sex ratio was 0.7/1 and gross total removal was obtained in 16 cases (84%), subtotal in three (16%). The only complication was a cerebrospinal fluid leak requiring spinal drainage. The median in-hospital stay was 2.5 days. Sixteen patients experienced clinical improvement (84%) and no changes were observed in three (16%). Residual tumor was seen in two cases (11%). Growth hormone levels ‹ 2 ng/dl were seen in 17 cases (89%) and only two patients (11%) had a level › 2 ng/dl. Insulin-like growth factor-1 levels were normalized in 16 cases (84%) and remained elevated in three patients (16%). One patient presented an isolated elevated level of insulin-like growth factor-1. Patients with residual tumor and elevated growth hormone and insulin-like growth factor-1 levels underwent complementary radiosurgery. Conclusions: The endoscopic endonasal transsphenoidal approach seems to be useful in acromegaly, with a high rate of clinical and biochemical cure among other benefits.


REFERENCES

  1. Vance ML, Laws ER Jr. Role of medical therapy in the management of acromegaly. Neurosurgery. 2005;56:877-85.

  2. Vance ML. Treatment of patients with a pituitary adenoma: one clinican’s experience. Neurosurg Focus. 2004;16(4):Article 1.

  3. Ben-Shlomo A. Acromegaly. Endocrinol Metab Clin North Am. 2008;37:101-22.

  4. Avramadis A, Polyzos SA, Efstathiadou Z, Kita M. Sustained clinical inactivity and stabilization of GH/IGF-1 levels in na acromegalic patient after discontinuation of somatostatin analogue treatment. Endocrine Journal. 2008;55:351-7.

  5. Sakay H, Tsuchiya K, Nakayama F, et al. Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J. 2008;55(5):853-9.

  6. Bengtsson BA, Eden S, Ernest I, Odén A, Sjögren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327-35.

  7. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology. 2003;58:86-91.

  8. Nomikos O, Buchfelder M, Fahlbush R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol. 2005;152:379-87.

  9. Giustina A, Barkan A, Casanueva F, et al. Criteria for Cure of Acromegaly: A Consensus Statement. J Clin Endocrinol Metab. 2000;85:526-9.

  10. Ayuk J, Sheppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord. 2008;9:33-9.

  11. Luque-Ramírez M, Paramo C, Varela da Costa C, García-Mayor RV. Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest. 2007;30:541-5.

  12. Laws ER. Surgery for acromegaly: Evolution of the techniques and outcomes. Rev Endocr Metab Disord. 2008;9:67-70.

  13. Ezzat S. Pharmacological approach to the treatment of acromegaly. Neurosurg Focus. 2004;16:Article 3.

  14. Landolt AM, Lomax N, Scheib SG, Girard J. Gamma Knife surgery after fractionated radiotherapy for acromegaly. J Neurosurg. 2006;105:31-6.

  15. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignanó T, Giovanelli M. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg. 2006;104:899-906.

  16. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg. 2007;106:833-8.

  17. Witt TC. Stereotactic radiosurgery for pituitary tumors. Neurosurg Focus. 2003;14(5):Article 10.

  18. Guiot A. Transsphenoidal approach in surgical treatment of pituitary adenomas: General principles and indications in nonfunctioning adenoma. En: Diagnosis and Treatment of Pituitary Tumors. Kohler PO, Ross GT (Eds). Excerpta Medica Amsterdam. 1973:159-78.

  19. Hardy J. Trans-sphenoidal approach to the pituitary gland, En: Neurosurgery Vol 1. Wilkins RH, Rengachary SS (Eds). New York: McGraw-Hill; 1985. p. 889-98.

  20. Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 1969;16:185-217.

  21. Laws ER Jr. Transsphenoidal hypophysectomy. J Neurosurg. 2007; 107:458.

  22. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hor- mone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83:3411-8.

  23. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of ‘abnormal’ nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004; 89:495-500.

  24. Ikeda H, Jokura H, Yoshimoto T. Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. J Neurosurg. 2001;95:285-91.

  25. Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. 2001;48:1239-45.

  26. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992;21:669-92.

  27. Abbassioun K, Amirjamshidi M, Mehrazin A, et al. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years. Surg Neuro. 2006;66:26-31.

  28. Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 1988;68:854-67.

  29. Losa M, Oeckler R, Schopohl J, Müller OA, Alba-López J, Von Werder K. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly. J Neurosurgery. 1989;70:561-7.

  30. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg. 1993;78:205-15.

  31. Davis DH. Results of surgical treatment for growth hormone secreting pituitary adenomas. J Neurosurg. 1993;79:70-5.

  32. Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical Endocrinology. 1996;45:407-13.

  33. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998;89:353-8.

  34. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419-26.

  35. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly – the experience of a dedicated pituitary surgeon. QJM. 1999;92:741-5.

  36. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50:561-7.

  37. Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Hormone Res. 2000;53(Suppl 3):71-5.

  38. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86;4072-7.

  39. Black PM, Zervas NT, Candia G. Incidence and management of complications of transsphenoidal operation for pituitary adenomas. Neurosurgery. 1987;20:920-4.

  40. Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg. 1997;87:44-51.

  41. Jho HD, Carrau RL, Ko Y. Endoscopic pituitary surgery, En: Neurosurgical Operative Atlas Vol 5. Wilkins RH, Rengachary SS (Eds). American Association of Neurological Surgeons Park Ridge. 1996:112.

  42. Cappabianca P, Alfieri A, Colao A, Ferone D, Lombardi G, De Divitiis E. Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. Skull Base Surg. 1999;9:109-17.

  43. Charalampaki P, Reisch R, Ayad A, et al. Endoscopic endonasal pituitary surgery: surgical and outcome analysis of 50 cases. J Clin Neurosci. 2007;14:410-5.

  44. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509-17.

  45. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;25;3:17.

  46. Santoro A, Minniti G, Ruggeri A, Esposito V, Jaffrain-Rea ML, Delfini R. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results. Surg Neurol. 2007;68:513-8.

  47. Bush ZM, Vance ML. Management of acromegaly: Is there a role for primary medical therapy? Rev Endocr Metab Disord. 2008;9:83-94.

  48. Alexopoulou O, Bex M, Abs R, T’sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly; J Clin Endocrinol Metab. 2008;93:1324-30.




2020     |     www.medigraphic.com